COX-2 promoter region polymorphisms in multiple sclerosis: Lack of association of -765G>C with disease risk

International Journal of Immunogenetics

Volumn 34, Issue 2, 2007, Pages 71-74

  Mazzola, S ^a   Lira, M Gomez ^a   Benedetti, M D ^a   Salviati, A ^a   Ottaviani, S ^a   Malerba, G ^a   Ortombina, M ^a   Pignatti, P F ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

CYCLOOXYGENASE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RISK;

EID: 33947200727     PISSN: 17443121     EISSN: 1744313X     Source Type: Journal    
DOI: 10.1111/j.1744-313X.2007.00675.x     Document Type: Article

References (24)

1. Aloisi, F., Serafini, B. & Adorini, D. (2000) Glia-T cell dialogue. Journal of Neuroimmunology, 107, 111.
2. Appleby, S.B., Ristimaki, A., Neilson, K., Narko, K. & Hla, T. (1994) Structure of the human cyclo-oxygenase-2 gene. Biochemical Journal, 302, 723.
3. Chun, K.S. & Surh, Y.J. (2004) Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochemical Pharmacology, 68, 1089.
4. Cipollone, F., Toniato, E., Martinotti, S., Fazia, M., Iezzi, A., Cuccurullo, C. et al. (2004) Identification of New Elements of Plaque Stability (INES) Study Group: a polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA, 291, 2221.
5. Compston, A. & Coles, A. (2002) Multiple sclerosis. Lancet, 359, 1221.
6. Fritsche, E., Baek, S.J., King, L.M., Zeldin, D.C., Eling, T.E. & Bell, D.A. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. Journal of Pharmacology and Experimental Therapeutics, 299, 468.
7. Gasparini, P., Bonizzato, A., Dognini, M. & Pignatti, P.F. (1992) Restriction site generating-polymerase chain reaction (RG-PCR) for the probeless detection of hidden genetic variation: application to the study of some common cystic fibrosis mutations. Molecular Cell Probes, 6, 1.
8. Hafler, D.A., Slavik, J.M., Anderson, D.E., O'Connor, K.C., De Jager, P. & Baecher-Allan, C. (2005) Multiple sclerosis. Immunological Reviews, 204, 208.
9. Kelley, K.A., Ho, L., Winger, D., Freire-Moar, J., Borelli, C.B., Aisen, P.S. & Pasinetti, G.M. (1999) Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. American Journal of Pathology, 155, 995.
10. Kosaka, T., Miyata, A., Ihara, H., Hara, S., Sugimoto, T., Takeda, O., Takahashi, E. & Tanabe, T. (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. European Journal of Biochemistry, 221, 889.
11. Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B., Comi, G. & Filippini, M. (2002) Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurology, 1, 499.
12. McDonald, J.W., Althomsons, S.P., Hyrc, K.L., Choi, D. & Goldberg, M.P. (1998) Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nature Medicine, 4, 291.
13. McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology, 50, 121.
14. Papafili, A., Hill, M.R., Brull, D.J., McAnulty, R.J., Marshall, R.P., Humphries, S.E. & Laurent, G.J. (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1631.
15. Pepys, M.B. & Hirschfield, G.M. (2003) C-reactive protein: a critical update. Journal of Clinical Investigation, 111, 1805.
16. Piani, D., Frei, K., Do, K.Q., Cuénod, M. & Fontana, A. (1991) Murine brain macrophages induce NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neuroscience Letters, 133, 159.
17. Pitt, D., Werner, P. & Raine, C.S. (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nature Medicine, 6, 67.
18. Poser, C.M., Paty, D.W., Scheinberg, L., McDonald, W.I., Davis, F.A., Ebers, G.C., Johnson, K.P., Sibley, W.A., Silberberg, D.H. & Tourtellotte, W.W. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology, 13, 227.
19. Roesler, W.J., Vandenbark, G.R. & Hanson, R.W. (1988) Cyclic AMP and the induction of eukaryotic gene transcription. Journal of Biological Chemistry, 263, 9063.
20. Rose, J.W., Hill, K.E., Watt, H.E. & Carlson, N.G. (2004) Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. Journal of Neuroimmunology, 149, 40.
21. Shi, J., Misso, N.L., Duffy, D.L., Thompson, P.J. & Kedda, M.A. (2004) A functional polymorphism in the promoter region of the cyclooxygenase-2 gene is not associated with asthma and atopy in an Australian population. Clinical Experimental Allergy, 34, 1714.
22. Smith, W.L., Garavito, R.M. & DeWitt, D.L. (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. Journal of Biological Chemistry, 271, 33157.
23. Ulrich, C.M., Whitton, J., Yu, J.H., Sibert, J., Sparks, R., Potter, J.D. & Bigler, J. (2005) PTGS2 (COX-2) -765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiology Biomarkers &Prevention, 14, 616.
24. Werner, P., Pitt, D. & Raine, C.S. (2000) Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? Journal of Neural Transmission, 60 Suppl., 375.